Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Share-based Compensation (2019 - 2025)

Historic Share-based Compensation for Benitec Biopharma (BNTC) over the last 7 years, with Q2 2025 value amounting to $6.1 million.

  • Benitec Biopharma's Share-based Compensation rose 124559.47% to $6.1 million in Q2 2025 from the same period last year, while for Jun 2025 it was $17.4 million, marking a year-over-year increase of 199951.81%. This contributed to the annual value of $17.4 million for FY2025, which is 199951.81% up from last year.
  • Latest data reveals that Benitec Biopharma reported Share-based Compensation of $6.1 million as of Q2 2025, which was up 124559.47% from $7.7 million recorded in Q1 2025.
  • In the past 5 years, Benitec Biopharma's Share-based Compensation registered a high of $7.7 million during Q1 2025, and its lowest value of -$48000.0 during Q4 2022.
  • Over the past 5 years, Benitec Biopharma's median Share-based Compensation value was $237000.0 (recorded in 2021), while the average stood at $1.1 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first plummeted by 12008.37% in 2022, then skyrocketed by 393333.33% in 2025.
  • Quarter analysis of 5 years shows Benitec Biopharma's Share-based Compensation stood at $239000.0 in 2021, then plummeted by 120.08% to -$48000.0 in 2022, then skyrocketed by 293.75% to $93000.0 in 2023, then surged by 3274.19% to $3.1 million in 2024, then surged by 94.68% to $6.1 million in 2025.
  • Its Share-based Compensation was $6.1 million in Q2 2025, compared to $7.7 million in Q1 2025 and $3.1 million in Q4 2024.